This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Go to /pro/cpd-dashboard page

This page is worth 0.05 CPD hours. CPD dashboard

Go to /pro/cpd-dashboard page

This page is worth 0.05 CPD hours. Upgrade to Pro

Go to /sign-in page

You can view 5 more pages before signing in

Go to /pro/cpd-dashboard page

This page is worth 0.05 CPD hours. CPD dashboard

Go to /pro/cpd-dashboard page

This page is worth 0.05 CPD hours. Upgrade to Pro

Fatal familial insomnia (FFI)

Authoring team

Fatal familial insomnia (FFI)

  • fatal familial insomnia (FFI) is a very rare, invariably fatal, autosomal dominant neurodegenerative prion disease caused by a mutation in the prion protein (PRNP) gene (1,2,3)
  • genetics and family history:
    • caused by a point mutation at codon 178 of the PRNP gene on chromosome 20p13 (c.532G>A, p.Asp178Asn / D178N) in coupling with methionine at polymorphic codon 129 (M129) on the mutant allele (1,2)
    • while inherited in an autosomal dominant manner, a definite family history is documented in approximately 82% of cases; therefore, the absence of a known family history does not exclude FFI (4)
  • epidemiology and age at onset:
    • inherited prion diseases account for approximately 10% to 15% of all human prion disease cases (overall prion disease incidence is 1 to 1.5 new cases per million population annually) (2)
    • although symptoms frequently present in mid-adulthood, a pooled analysis of 131 FFI patients demonstrated a mean age at onset of 47.5 years, with a wide range from 17 to 76 years (2,4)

Pathophysiology

  • selective thalamic degeneration: neuropathological hallmarks include severe, selective neuronal loss (often exceeding 90%) and reactive gliosis predominantly within the anteroventral (AV) and mediodorsal (MD) thalamic nuclei, which form the limbic and visceral portion of the thalamus (2,3)
  • disruption of sleep-wake architecture: degeneration of the MD thalamic nuclei severs relay pathways between the thalamic reticular nucleus and the prefrontal cortex, abolishing sleep spindles and preventing transition into physiological non-rapid eye movement (NREM) and rapid eye movement (REM) sleep (3)
  • central autonomic and endocrine dysregulation: disconnection of cortico-limbic inhibitory control over the hypothalamus shifts autonomic homeostasis toward persistent sympathetic activation and flattens vegetative and hormonal circadian oscillations (including melatonin, prolactin, growth hormone, and adrenocorticotropic hormone [ACTH]/cortisol rhythms) (2,3)

Clinical features

  • core clinical triad (typically progressing over less than 2 years) (2):
    • organic sleep disturbance: aggressively progressive, intractable insomnia with loss of circadian sleep-wake rhythm, sleep fragmentation, vivid dreaming or dream-like status during wakefulness (oneiric stupor), periodic limb movements, central sleep apnoea, and laryngeal stridor (agrypnia excitata) (2,3)
    • autonomic and endocrine dysfunction: sympathetic hyperactivity manifesting as tachycardia, systemic hypertension, tachypnoea, hyperhidrosis (excessive sweating), hyperthermia, increased lacrimation, constipation, sexual dysfunction, and marked weight loss (>10 kg over 6 months) (2,3)
    • neuropsychiatric and motor impairments: attentional deficits, short-term memory impairment, slowing thought processing, depression, apathy, panic or phobias, visual hallucinations, diplopia, dysarthria, dysphagia, gait instability, ataxia, myoclonus, and pyramidal or extrapyramidal signs (1,2)
  • clinical staging (4 stages) (2):
    • stage 1: subacute onset of worsening insomnia accompanied by psychiatric symptoms (phobias, paranoia, panic attacks) and lucid dreaming over a few months (2)
    • stage 2: progressive worsening of insomnia and psychiatric features with hallucinations and marked sympathetic hyperactivity (lasting approximately 5 months) (2)
    • stage 3: total insomnia and complete disruption of the sleep-wake cycle (lasting approximately 3 months) (2)
    • stage 4: rapid cognitive decline and dementia with loss of voluntary movement and speech (akinetic mutism), progressing to coma and death (lasting 6 months or longer) (2)

Investigations

  • definitive genetic testing: PRNP gene sequencing to identify the pathogenic c.532G>A (p.Asp178Asn / D178N) variant and determine codon 129 genotype is the definitive diagnostic test (1,2,4)
  • cerebrospinal fluid (CSF) analysis and RT-QuIC limitations:
    • standard CSF biomarkers (such as 14-3-3 protein) are non-specific (2)
    • unlike sporadic Creutzfeldt-Jakob disease (sCJD), where CSF real-time quaking-induced conversion (RT-QuIC) is highly sensitive, CSF RT-QuIC has very low sensitivity in FFI (with UK cohort data showing no RT-QuIC conditions detecting the FFI variant); a negative RT-QuIC result does not exclude FFI (5,6)
  • polysomnography (PSG): demonstrates marked reduction in total sleep time and sleep efficiency, early disappearance of sleep spindles and K-complexes, loss of slow-wave sleep, and disrupted REM transitions (2,3)
  • neuroimaging:
    • brain MRI helps exclude alternative structural, inflammatory, or vascular pathologies and may demonstrate restricted diffusion or atrophy in the thalamus (1,2)
    • 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) characteristically shows marked hypometabolism in the thalamus and cingulate cortex while sparing the occipital lobe (2)
    • electroencephalography (EEG): typically shows non-specific background slowing without the periodic sharp-wave complexes classically associated with sporadic CJD (2)

Management, prognosis, and UK referral pathways

  • management:
    • no curative treatment exists; management focuses on multidisciplinary symptomatic relief, palliative care, and early hospice involvement (1,2)
    • conventional sedatives (benzodiazepines, barbiturates) are generally ineffective for FFI-related insomnia and may worsen confusion (2)
    • discontinue medications that exacerbate cognitive impairment or insomnia, manage dysphagia and autonomic complications, and offer psychosocial support and predictive genetic counselling to at-risk family members (1,2)
  • prognosis:
    • universally fatal; in a pooled series of 131 patients, mean disease duration was 13.2 months (range 2 to 48 months), while wider clinical reviews report an average course of 12 to 18 months (2,4)
    • survival duration differs markedly according to the PRNP codon 129 polymorphism on the non-mutated second allele: homozygotes (129MM) have a significantly shorter mean survival (approximately 11 months) compared with heterozygotes (129MV, approximately 27 months) (2,4)
  • UK referral and public health notification:
    • all suspected cases of prion disease in the UK should be referred to the NHS National Prion Clinic (University College London Hospitals NHS Foundation Trust, London) for specialist diagnostic evaluation, genetic testing coordination, and clinical support (7)
    • Creutzfeldt-Jakob disease (CJD), including inherited prion diseases such as FFI, is a notifiable disease and must be notified to the local UKHSA Health Protection Team (7)

References:

  1. Rose DK, Liu AJ. A case of fatal familial insomnia: diagnostic and therapeutic approaches. Neurocase. 2022;28(2):131-134. doi: 10.1080/13554794.2021.2025249.
  2. Sankari A, Bollu PC. Fatal Familial Insomnia. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; updated 25 February 2024.
  3. Lugaresi E, Tobler I, Gambetti P, Montagna P. The pathophysiology of fatal familial insomnia. Brain Pathol. 1998;8(3):521-526.
  4. Zhang J, Chu M, Tian Z, et al. Clinical profile of fatal familial insomnia: phenotypic variation in 129 polymorphisms and geographical regions. J Neurol Neurosurg Psychiatry. 2022;93(3):291-297. doi: 10.1136/jnnp-2021-327247.
  5. Rhoads DD, Wrona A, Foutz A, et al. Diagnosis of prion diseases by RT-QuIC results in improved surveillance. Neurology. 2020;95(8):e1017-e1026. doi: 10.1212/WNL.0000000000010086.
  6. Mok TH, Nihat A, Luk C, et al. Bank vole prion protein extends the use of RT-QuIC assays to detect prions in a range of inherited prion diseases. Brain. 2023;146(6):2532-2547. doi: 10.1093/brain/awad101.
  7. UK Chief Medical Officers' letter to neurologists (29 August 2025) and NHS National Prion Clinic (UCLH) referral guidance (https://www.ucl.ac.uk/brain-sciences/national-prion-clinic/referrals-and-contact (https://www.ucl.ac.uk/brain-sciences/national-prion-clinic/referrals-and-contact)).

 


Related pages

Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.